Does an optimum treatment for high-risk low-grade gliomas exist?
Mené sur 477 patients atteints d'un gliome de faible grade, cet essai de phase III compare l'intérêt, du point de vue de la survie sans progression, de la toxicité et de la qualité de vie des patients, du témozolomide et d'une radiothérapie standard
Diffuse low-grade gliomas (grade II according to WHO's 2016 classification) represent a heterogeneous group of tumours in terms of outcome, with widely varying survival times ranging from just a few years to 20 years. Maximal safe resection is the initial optimum treatment and adjuvant treatments after surgery are used in high-risk patients. However, the choice and timing of adjuvant treatments are now controversial, both because of the rarity of these tumours which restricts the questions that can be answered in a reasonable timeframe in randomised clinical trials, and the dramatic development of molecular and technology advancements.
The Lancet Oncology , commentaire, 2015